Elizabeth Nabel (Elise Amendola/AP Images)

Eliz­a­beth Nabel steps down as pres­i­dent of Brigham and Wom­en's Hos­pi­tal to team up with hus­band's biotech joint — re­port

The pres­i­dent of Brigham and Women’s Hos­pi­tal, a renowned non­prof­it med­ical cen­ter in Boston, is re­port­ed­ly step­ping down from her po­si­tion to join her hus­band — Sanofi’s for­mer CSO — in the biotech sec­tor.

Eliz­a­beth Nabel and BWH an­nounced she would de­part as pres­i­dent on March 1 af­ter spend­ing 11 years at the hos­pi­tal. She will team up with her hus­band, Gary Nabel, who left the top R&D job at Sanofi in Oc­to­ber to launch his own biotech de­vel­op­ing im­mune ther­a­pies for can­cer and in­fec­tious dis­eases, ac­cord­ing to the Boston Globe

“I re­al­ly want to spend time dri­ving biotech in­no­va­tion by ad­vis­ing com­pa­nies and serv­ing on boards,” she told the Globe. “This is where I be­lieve I can have the great­est im­pact.”

It’s not im­me­di­ate­ly clear how far off the ground the Nabels’ new biotech is. BWH de­clined to com­ment to End­points News on Eliz­a­beth Nabel’s be­half.

Nabel has served as the pres­i­dent of BWH for the last 11 years, and told the Globe she had planned to step down af­ter a decade at the helm. But the Covid-19 pan­dem­ic com­pli­cat­ed mat­ters and she de­cid­ed to stay on un­til the first vac­cines had been au­tho­rized.

Her run at BWH has been high­ly suc­cess­ful for the hos­pi­tal, as she led fundrais­ing ef­forts since 2010 that have brought in $1.75 bil­lion, rough­ly half of which went to re­search. She al­so helped grow the hos­pi­tal’s rev­enue to $5 bil­lion per year.

Nabel’s role as pres­i­dent hasn’t been her on­ly job over that time pe­ri­od, how­ev­er, as she was a board mem­ber for Mod­er­na from 2015 un­til this past Ju­ly. She re­signed from that po­si­tion, fol­low­ing OWS chief Mon­cef Slaoui out the door, af­ter in­creas­ing scruti­ny in­to the tim­ing of Mod­er­na ex­ec­u­tives’ stock trans­ac­tions.

Specif­i­cal­ly with re­gards to Nabel, con­cerns arose over the op­tics of Nabel run­ning a hos­pi­tal where Mod­er­na test­ed its Covid-19 vac­cines. At the time, Flag­ship chief and Mod­er­na chair Noubar Afeyan said the move was made out of “an abun­dance of cau­tion” to avoid the ap­pear­ance of a con­flict of in­ter­est.

BWH had not be­gun re­cruit­ing par­tic­i­pants for Mod­er­na’s Phase III study when Nabel re­signed, and was one of 87 sites na­tion­wide where vol­un­teers re­ceived dos­es of the now-au­tho­rized vac­cine.

On Ju­ly 15, Nabel re­deemed about 60,000 of an avail­able 168,868 Mod­er­na stock op­tions, and sub­se­quent­ly sold 73,975 shares as part of a trad­ing plan re­vised in late May. The sale net­ted Nabel $6.5 mil­lion.

Sim­i­lar trad­ing plans en­act­ed by Mod­er­na ex­ecs Stéphane Ban­cel, Stephen Hoge and Tal Zaks drew heavy me­dia at­ten­tion last year, as Zaks’ plan was amend­ed in March and Hoge’s in June. Ban­cel’s had been in place since 2018.

Un­lock­ing ESG strate­gies for growth with Gilead Sci­ences

RBC Capital Markets explores what is material in ESG for biopharma companies with the ESG leads at Gilead Sciences. Gilead has long focused on sustainability but recognized a more robust framework was needed. Based on a materiality assessment, Gilead’s ESG strategy today focuses first on drug access and pricing, while also addressing D&I and climate change. Find out why Gilead’s board is “acutely aware” of the contribution that ESG makes to firm’s overall success.

What con­tro­ver­sy? Eli Lil­ly plots Alzheimer's BLA fil­ing lat­er this year as FDA taps more an­ti-amy­loid drugs as break­throughs

The FDA is keeping the good news coming for Alzheimer’s drug developers. And Eli Lilly is taking them up on it.

Amid continued controversy around whether Biogen’s new flagship drug, Aduhelm, should have been approved at all — and swelling, heated debates surrounding its $56,000 price tag — the agency had no issue handing them and their Japanese partner Eisai a breakthrough therapy designation for a second anti-amyloid beta antibody, lecanemab, late Wednesday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

Hervé Hoppenot, Incyte CEO (Jeff Rumans)

ODAC echoes FDA con­cern over In­cyte PD-1, as Paz­dur sig­nals broad­er shift for ac­cel­er­at­ed ap­proval

After the FDA lambasted their PD-1 ahead of an adcomm earlier this week, Incyte ran into new trouble Thursday as ODAC panelists voted against an accelerated OK by a wide margin.

Members of the Oncologic Drugs Advisory Committee recommended with a 13-4 vote to defer a regulatory decision on Incyte’s retifanlimab until after more data can be collected from a placebo-controlled trial. The PD-1 therapy is due for a PDUFA date in late July after receiving priority review earlier this year.

Karen Flynn, Catalent

Q&A: When the pan­dem­ic struck, Catal­en­t's CCO had just joined the team

Karen Flynn came aboard Catalent’s team just in time.

The company was going through a surge of changes, and she had been brought over from her role as CCO of West Pharmaceutical Services to serve in the same capacity for the New Jersey-based CDMO. Then a few months later, the pandemic was in full-force.

Since then, Catalent’s been in hyper-expansion mode. In early May, it acquired Promethera’s Hepatic Cell Therapy Support SA subsidiary and its 32,40-square-foot facility in Gosselies, Belgium. Prior to that, the company acquired Belgian CDMO Delphi Genetics, wrapped up the expansion of an already-existing site in Madison, WI and added an ultra-low temperature freezer partner in Sterling. As Emergent has botched millions of doses of AstraZeneca’s vaccine, the company has swooped in to move that production to its Maryland plant as well.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

New FDA doc­u­ments show in­ter­nal dis­sent on Aduhelm ap­proval

In a lengthy review document and a pair of memos from top officials, the FDA released on Tuesday night its most detailed argument yet for approving Biogen’s intensely controversial Alzheimer’s drug aducanumab.

The documents amount to an agency attempt to quench the firestorm their decision kindled, as outside advisors members resigned and experts warned that an unproven drug now could stretch Medicare’s budget to a breaking point. Ultimately, the documents show how CDER director Patrizia Cavazzoni and Office of New Drugs director Peter Stein both concurred with FDA neuroscience head Billy Dunn on the accelerated approval while the staff at FDA’s Office of Biostatistics did not think an approval was warranted.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

Richard Pazdur (vis AACR)

FDA en­cour­ages in­clud­ing in­cur­able can­cer pa­tients in tri­als, re­gard­less of pri­or ther­a­pies

The FDA on Thursday called to include those with incurable cancers (when there is no potential for cure or for prolonged/near normal survival) in appropriate clinical trials, regardless of whether they have received existing alternative treatments.

Historically, many cancer clinical trials have required that participating patients previously received multiple therapies, according to Richard Pazdur, director of the FDA’s Oncology Center of Excellence.

On heels of Aduhelm ap­proval, Bris­tol My­ers jumps back in­to Alzheimer's race

Bristol Myers Squibb last put major resources behind an Alzheimer’s drug nearly a decade ago, when their own attempt at targeting amyloid flamed out in mid-stage studies. They invented another molecule, a Tau-targeted antibody, but jettisoned it to Biogen in 2017 as they dropped out of neuroscience altogether.

But on Thursday, the New York pharma announced they were getting back in the game. Bristol Myers exercised an $80 million option to bring a tau-targeted antibody from Prothena into a Phase I study. The opt-in, which Bristol Myers triggered ahead of analyst expectations, opens the door for another $1.7 billion in milestones down the road.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

James Peyer, Cambrian

Can a cell ther­a­py treat mus­cu­lar dy­s­tro­phy? A Ger­man bil­lion­aire's an­ti-ag­ing start­up is try­ing to find out

Gene therapy companies have faced huge hurdles trying to deliver healthy genes into muscular dystrophy patients’ muscle cells, so here’s an idea: Why don’t we just replace the muscle cells themselves?

Over the last two years, Vita Therapeutics has been exploring that possibility, building on early stem cell work from Johns Hopkins professor Peter Andersen. And on Tuesday they announced a $32 million Series A to begin to move their first therapy into the clinic, where they hope it will help rebuild muscle in patients with a type of dystrophy that afflicts the arms and legs.

Alexis Borisy (file photo)

EQRx and Ex­sci­en­tia, a pair of self-styled dis­rup­tors, team up to over­turn the drug pric­ing ap­ple cart

The biotech industry has seen no shortage of innovation in recent years, but in one area — drug pricing — the field has been anything but innovative. Now, two brash startups taking different roads to upset the drug pricing model will partner up to create a sort of “super-disruptor.”

EQRx and UK-based AI specialist Exscientia will team up on a discovery-through-commercialization collaboration the partners hope will work better than the sum of its parts to bring cheaper medicines to patients faster, the companies said Thursday.